KR20190079698A - 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 - Google Patents

조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 Download PDF

Info

Publication number
KR20190079698A
KR20190079698A KR1020197018445A KR20197018445A KR20190079698A KR 20190079698 A KR20190079698 A KR 20190079698A KR 1020197018445 A KR1020197018445 A KR 1020197018445A KR 20197018445 A KR20197018445 A KR 20197018445A KR 20190079698 A KR20190079698 A KR 20190079698A
Authority
KR
South Korea
Prior art keywords
residue
monoclonal antibody
antibody
tfpi
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197018445A
Other languages
English (en)
Korean (ko)
Inventor
쯔오즈시 왕
존 머피
토비아스 마르쿠아르트
디터 모스마이어
Original Assignee
바이엘 헬스케어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190079698(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 헬스케어 엘엘씨 filed Critical 바이엘 헬스케어 엘엘씨
Publication of KR20190079698A publication Critical patent/KR20190079698A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197018445A 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 Ceased KR20190079698A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
US61/471,101 2011-04-01
PCT/US2012/031538 WO2012135671A2 (en) 2011-04-01 2012-03-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028821A Division KR101995302B1 (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체

Publications (1)

Publication Number Publication Date
KR20190079698A true KR20190079698A (ko) 2019-07-05

Family

ID=46932389

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197018445A Ceased KR20190079698A (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체
KR1020137028821A Expired - Fee Related KR101995302B1 (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137028821A Expired - Fee Related KR101995302B1 (ko) 2011-04-01 2012-03-30 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체

Country Status (37)

Country Link
US (5) US20140294832A1 (enExample)
EP (1) EP2694544B1 (enExample)
JP (4) JP6170903B2 (enExample)
KR (2) KR20190079698A (enExample)
CN (2) CN107090046A (enExample)
AU (3) AU2012236296A1 (enExample)
BR (1) BR112013025376A2 (enExample)
CA (2) CA3068997A1 (enExample)
CL (1) CL2013002811A1 (enExample)
CO (1) CO6890074A2 (enExample)
CR (1) CR20130499A (enExample)
CU (1) CU20130128A7 (enExample)
CY (1) CY1121538T1 (enExample)
DK (1) DK2694544T3 (enExample)
DO (1) DOP2013000218A (enExample)
EA (2) EA201991704A3 (enExample)
EC (1) ECSP13012913A (enExample)
ES (1) ES2722824T3 (enExample)
GT (1) GT201300229A (enExample)
HK (1) HK1243426A1 (enExample)
HR (1) HRP20190467T1 (enExample)
HU (1) HUE042706T2 (enExample)
IL (4) IL228633B (enExample)
LT (1) LT2694544T (enExample)
MX (1) MX2013011218A (enExample)
MY (2) MY190951A (enExample)
PE (1) PE20141149A1 (enExample)
PH (4) PH12013502039B1 (enExample)
PL (1) PL2694544T3 (enExample)
PT (1) PT2694544T (enExample)
RS (1) RS58633B1 (enExample)
SG (2) SG193594A1 (enExample)
SI (1) SI2694544T1 (enExample)
TR (1) TR201905101T4 (enExample)
UA (1) UA113623C2 (enExample)
WO (1) WO2012135671A2 (enExample)
ZA (1) ZA201308169B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962563B2 (en) 2009-12-21 2015-02-24 Baxter International, Inc. TFPI inhibitors and methods of use
LT2379096T (lt) 2008-12-19 2019-12-27 Baxalta GmbH Tfpi inhibitoriai ir vartojimo būdai
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
JP6170903B2 (ja) * 2011-04-01 2017-07-26 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN107266574A (zh) * 2012-03-30 2017-10-20 拜尔健康护理有限责任公司 蛋白酶调节的抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014140240A1 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
CN113788897A (zh) 2013-03-15 2021-12-14 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
CN105473619B (zh) * 2013-07-19 2020-12-15 诺和诺德股份有限公司 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
US11279771B2 (en) * 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
CN107428838B (zh) * 2015-02-25 2021-01-01 财团法人牧岩生命科学研究所 结合tfpi的新型抗体以及包含所述抗体的组合物
KR20230074843A (ko) * 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379600B2 (en) * 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
SG183443A1 (en) * 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP6170903B2 (ja) * 2011-04-01 2017-07-26 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
NZ615969A (en) 2016-01-29
EA201991704A3 (ru) 2020-06-30
IL274686A (en) 2020-06-30
JP2017113019A (ja) 2017-06-29
IL257145A (en) 2018-03-29
KR101995302B1 (ko) 2019-07-02
RS58633B1 (sr) 2019-05-31
BR112013025376A2 (pt) 2017-07-25
PH12013502039A1 (en) 2013-12-16
SI2694544T1 (sl) 2019-06-28
HUE042706T2 (hu) 2019-07-29
EA201991704A2 (ru) 2020-03-31
TR201905101T4 (tr) 2019-05-21
US20170107298A1 (en) 2017-04-20
US20140294832A1 (en) 2014-10-02
EA034214B1 (ru) 2020-01-17
PT2694544T (pt) 2019-04-02
US20220041752A1 (en) 2022-02-10
MX2013011218A (es) 2013-10-17
AU2019201814A1 (en) 2019-04-04
CL2013002811A1 (es) 2014-02-28
PE20141149A1 (es) 2014-08-28
MY165499A (en) 2018-03-27
US20190194353A1 (en) 2019-06-27
IL228633B (en) 2018-03-29
EP2694544A4 (en) 2015-03-25
CA2831907A1 (en) 2012-10-04
WO2012135671A2 (en) 2012-10-04
JP2021019619A (ja) 2021-02-18
CA2831907C (en) 2020-03-24
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
CN107090046A (zh) 2017-08-25
JP2014511685A (ja) 2014-05-19
JP6170903B2 (ja) 2017-07-26
CN103797030B (zh) 2017-05-31
ECSP13012913A (es) 2014-02-28
CU20130128A7 (es) 2014-03-26
PH12019500439A1 (en) 2020-10-12
HK1243426A1 (zh) 2018-07-13
LT2694544T (lt) 2019-04-25
UA113623C2 (uk) 2017-02-27
EP2694544B1 (en) 2019-01-23
IL228633A0 (en) 2013-12-31
PL2694544T3 (pl) 2019-07-31
HRP20190467T1 (hr) 2019-05-03
PH12013502039B1 (en) 2013-12-16
DOP2013000218A (es) 2013-11-15
GT201300229A (es) 2014-11-13
AU2012236296A1 (en) 2013-10-24
CO6890074A2 (es) 2014-03-10
ES2722824T3 (es) 2019-08-19
CN103797030A (zh) 2014-05-14
EA201301107A1 (ru) 2014-11-28
CA3068997A1 (en) 2012-10-04
CR20130499A (es) 2013-10-24
IL283829A (en) 2021-07-29
CY1121538T1 (el) 2020-05-29
AU2017203105A1 (en) 2017-06-01
JP6363747B2 (ja) 2018-07-25
JP2018172411A (ja) 2018-11-08
WO2012135671A3 (en) 2012-12-13
ZA201308169B (en) 2016-03-30
DK2694544T3 (en) 2019-04-15
EP2694544A2 (en) 2014-02-12
IL274686B (en) 2021-09-30
US20180194857A1 (en) 2018-07-12
PH12019500441A1 (en) 2020-10-12
SG10201602606UA (en) 2016-04-28
SG193594A1 (en) 2013-10-30
KR20140019428A (ko) 2014-02-14

Similar Documents

Publication Publication Date Title
KR101995302B1 (ko) 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체
KR101974980B1 (ko) 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2013202745B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HK1197829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1197829B (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ615969B2 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190626

Application number text: 1020137028821

Filing date: 20131030

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190920

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20200224

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200623

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200224

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20190920

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I